Clostridium perfringens-Induced Necrotic Diseases: An Overview Original paper

What was reviewed?

This review examined the mechanisms by which Clostridium perfringens induces necrotic diseases through toxin production, microbiome interaction, immune modulation, and metabolic disruption, with emphasis on enteritis, myonecrosis, necrotizing enterocolitis, and foodborne disease. The authors analyzed how this Gram-positive anaerobe, a normal member of the intestinal microbiome, produces more than twenty toxins that damage epithelial barriers, impair immune responses, and disrupt vascular perfusion, enabling rapid bacterial expansion and tissue necrosis. Key toxins such as alpha toxin, beta toxin, epsilon toxin, enterotoxin, and NetB toxin originate from chromosomal or plasmid genes and function by disrupting cell membranes, impairing immune cell migration, and inducing cellular death. The review also explained how microbiome imbalance, epithelial injury, antibiotic exposure, and metabolic alterations facilitate pathogenic overgrowth and disease progression, demonstrating that virulence depends on coordinated host–microbiome–pathogen interactions rather than bacterial presence alone.

Who was reviewed?

The review synthesized findings from human clinical studies, animal infection models, microbiome sequencing studies, and experimental toxin investigations involving humans, poultry, livestock, and laboratory animals. These studies evaluated microbiome colonization patterns, toxin gene expression, immune response alterations, and microbiome compositional shifts associated with necrotic enteritis, gas gangrene, and enterocolitis. Research included analysis of neonatal stool microbiome samples, animal intestinal infection models, and toxin exposure studies demonstrating how C. perfringens transitions from a commensal microbiome organism into a virulent pathogen when microbiome balance and host immunity are disrupted. The diagram on page 3 illustrates that C. perfringens causes diseases across multiple hosts and organ systems, emphasizing its ability to persist within microbiomes while retaining pathogenic potential.

What were the most important findings?

The review found that Clostridium perfringens virulence depends on microbiome disruption, toxin-mediated epithelial injury, immune evasion, and metabolic exploitation of host-derived nutrients. Major microbial associations (MMAs) included increased abundance of C. perfringens in necrotic enteritis and neonatal necrotizing enterocolitis microbiomes, with microbiome imbalance characterized by increased Proteobacteria and reduced Firmicutes diversity, indicating dysbiosis promotes pathogen expansion. Toxins such as alpha toxin disrupt cell membranes, reduce immune cell infiltration, and impair vascular perfusion, while enterotoxin binds epithelial claudins, forming pores that induce apoptosis and barrier breakdown. NetB toxin and beta toxin induce intestinal necrosis and inflammation, further facilitating bacterial growth.

The review also demonstrated that microbiome metabolites regulate disease progression, as secondary bile acids such as deoxycholic acid inhibited C. perfringens growth and reduced inflammatory cytokine expression and intestinal damage. Immune suppression was another key mechanism, as alpha toxin prevented neutrophil migration, promoted vascular occlusion, and reduced pathogen clearance, allowing rapid tissue colonization. These findings confirmed that microbiome dysbiosis, toxin production, immune dysfunction, and metabolic disruption collectively drive disease pathogenesis.

What are the greatest implications of this review?

This review demonstrated that Clostridium perfringens functions as a microbiome-associated opportunistic pathogen whose virulence emerges when microbiome balance, epithelial integrity, or immune function is disrupted. The ability of microbiome metabolites to suppress pathogen growth highlights the protective role of microbiome stability in disease prevention. These findings emphasize the importance of microbiome preservation, early detection of toxin-producing strains, and development of microbiome-targeted therapies to prevent toxin-mediated necrotic disease. Understanding microbiome–immune–pathogen interactions provides critical insight for developing probiotics, metabolite-based therapies, and targeted antimicrobial strategies to reduce disease risk and improve clinical outcomes.